Overview

* Niagen Bioscience ( NAGE ) Q2 net sales rise 37% to $31.1 mln, beating estimates, per LSEG data

* Net income reaches $3.6 mln, up from breakeven in prior year period

* Company raises full-year 2025 revenue growth outlook to 22%-27%

Outlook

* Niagen Bioscience ( NAGE ) raises 2025 revenue growth outlook to 22%-27%

* Company expects slight improvement in gross margin year-over-year

* Sales and marketing expenses to rise, but decrease as percentage of sales

* General and administrative expenses to increase by $7.0 to $8.0 mln

Result Drivers

* TRU NIAGEN SALES - Sales reached $22.7 mln, growing 22%, driven by strong e-commerce performance

* NIAGEN INGREDIENT SALES - Increased 135% to $7.4 mln, including food-grade and pharmaceutical-grade sales

* GROSS MARGIN IMPROVEMENT - Increased 480 basis points to 65.0% due to changes in product and business mix

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $31.12 $28.30

mln mln (5

Analysts

)

Q2 Net $3.61

Income mln

Q2 Gross $20.23

Profit mln

Q2 $17.04

Operatin mln

g

Expenses

Q2 $3.18

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Niagen Bioscience Inc ( NAGE ) is $16.00, about 42.8% above its August 5 closing price of $9.16

* The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 55 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)